Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Alpha-2 Receptor Agonists Market size was over USD 2.5 billion in 2024 and is anticipated to cross USD 7.39 billion by 2037, growing at more than 8.7% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of alpha-2 receptor agonists is assessed at USD 2.68 billion.
This increase is due to the increased occurrence of hypertension and associated conditions. Approximately 1.28 billion persons worldwide, between the ages of 30 and 79, have hypertension, according to our study; low- and middle-income nations report the majority of instances.
Moreover, a number of metabolic illnesses have emerged globally due to the growing geriatric population and growing knowledge of behavioral and lifestyle changes. This has increased the need for specialized medications. Alpha-2 receptor agonists are becoming more and more popular as a therapeutic alternative because they can reduce blood pressure by inhibiting sympathetic activity in the brain.
Alpha-2 Receptor Agonists Sector: Growth Drivers and Challenges
Growth Drivers
- Rising prevalence of ocular - As ocular disorders such as glaucoma become more common, the need for alpha-2 receptor agonists in ophthalmic therapy increases for the treatment. Almost 2.7 million Americans, or approximately 1.9 percent of the population, are affected by glaucoma. Because they work well to lower intraocular pressure, these medications are useful for treating certain kinds of diseases.
- Expanding studies on alpha-2 receptor agonists - The pharmaceutical sector is always developing new medication formulations, delivery methods, and studies on the mechanisms of action of alpha-2 receptor agonists. The market is expanding because of these developments, which have greatly enhanced the medications' effectiveness and safety profile.
- Growing adoption as pain management solutions - Alpha-2 receptor agonists such as clonidine and dexmedetomidine are increasingly being used in pain management due to their analgesic properties. This utilization contributes to market growth, especially with the opioid crisis leading to a search for alternative pain relief options.
Challenges
- Side effects and tolerability issues - one of the significant challenges involves side effects associated with alpha-2 receptor agonists, such as dry mouth, sedation, hypotension, and dizziness. Improving drug tolerability while minimizing adverse effects remains a challenge in expanding their usage.
- Competition from alternative therapies.
- Resistance to change in clinical practices.
Alpha-2 Receptor Agonists Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.7% |
|
Base Year Market Size (2024) |
USD 2.5 billion |
|
Forecast Year Market Size (2037) |
USD 7.39 billion |
|
Regional Scope |
|
Alpha-2 Receptor Agonists Segmentation
Use (Hypertension, ADHD, Pain & Panic Disorder, ICU & Procedural Sedation)
In alpha-2 receptor agonists market, hypertension segment is poised to account for around 48% share by 2037. As a key risk factor for hypertension, this expansion is caused by an increase in the intake of unhealthy foods.
The number of persons who take medicine for hypertension or have a blood pressure of 140/90 mmHg or above is estimated to have doubled from 650 million to 1.3 billion between 1990 and 2020. Approximately 50% of hypertensive individuals globally are now ignorant of their illness. Alpha-2 receptor agonists are becoming more and more in demand as a result.
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
The hospital pharmacies segment in alpha-2 receptor agonists market is anticipated to garner a major revenue share. The growth of the hospital pharmacies segment can be attributed to the fact that a significant number of people around the world with hypertension and related disorders tend to choose hospital facilities for treatment.
Additionally, hospital pharmacies have quickly become the preferred distribution channel for the customization of pharmaceutical ingredients to create medications tailored to individuals' needs. The presence of skilled professionals who can perform such tasks in hospitals has led to an increase in demand for drug-compounding procedures in hospital pharmacies, which has contributed to the segment's growth.
Our in-depth analysis of the global market includes the following segments:
|
Use |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportAlpha-2 Receptor Agonists Industry - Regional Synopsis
North American Market Forecast
North America industry is set to dominate majority revenue share of 45% by 2037. This growth can be impelled by the growing number of people suffering from attention-deficit/hyperactivity disorder (ADHD). In the United States, nearly 8.7 million adults in the United States are dealing with this disorder. Around 60% of children with ADHD in the US also have at least one other mental, emotional, or behavioral condition, such as depression or anxiety. In addition, an estimated 77% of children diagnosed with ADHD in the United States receive treatment.
APAC Market Statistics
The market in Asia Pacific is predicted to garner significant revenue share during forecast period. The incidence of hypertension-related disorders is on the rise and is a growing concern in the Asian region. The use of alpha-2 receptor agonists is becoming increasingly common, as the prevalence of hypertension in urban adult populations of Asia has been found to vary between 15-35%, as per new criteria (140/90 mm Hg).
Companies Dominating the Alpha-2 Receptor Agonists Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck & Co., Inc.
- Viatris Inc.
- Amneal Pharmaceuticals LLC.
- Unichem Pharmaceuticals USA INC
- Seqens Group
- Teva Pharmaceuticals USA, Inc.
- Ajanta Pharma Ltd.
- Boehringer Ingelheim International GmbH.
- Dr. Reddy’s Laboratories
In the News
- Pfizer Inc., and Seagen, a multinational biotechnology business that specializes in antibody-drug conjugates (ADC), announced a formal merger agreement.
- Dr. Reddy's Laboratories Ltd. introduced a Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection, a therapeutically similar generic version of Precedex (dexmedetomidine hydrochloride) in 0.9% Sodium Chloride Injection that has been approved by the US Food and Drug Administration (USFDA
Author Credits: Radhika Pawar
- Report ID: 3265
- Published Date: Jan 03, 2025
- Report Format: PDF, PPT
